Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × bazlitoran × Lymphoid × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Rituximab 205 Cyclophosphamide 130 fludarabine 61 Vincristine 58 Methotrexate 57 Doxorubicin 49 fludarabine phosphate 46 Etoposide 46 Cytarabine 44 Prednisone 43 Lenalidomide 42 Filgrastim 40 Dexamethasone 39 Bortezomib 35 Whole-Body Irradiation 30 Radiotherapy 30 Gemcitabine 29 Melphalan 28 Mycophenolic Acid 27 Granulocyte Colony-Stimulating Factor 26 Bendamustine Hydrochloride 26 Antilymphocyte Serum 26 Alemtuzumab 26 obinutuzumab 25 Calcium Dobesilate 25 ibrutinib 24 venetoclax 23 Tacrolimus 23 Busulfan 23 Cyclosporine 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02092909 2019-09-10

8400-401

Idera Pharmaceuticals, Inc.

Phase 1/2 Terminated

31 enrolled 18 charts

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡